Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Wendys Co — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B), while Wendys Co trades at $6.24 (market cap $1.19B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 49.4× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Wendys Co for 77 Days on average.
| TAK | WEN | |
|---|---|---|
Market Cap | $58.74B | $1.19B |
Volume | 3,110,994 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $19.05 | $9.33 |
52-Week Low | $13.23 | $6.10 |
Typical Hold Time | 1 Days | 77 Days |
Enterprise Value | $86.65B | $4.92B |
Dividend Yield | 3.33% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wendy's stock trades at $6.23, up 1.96% today, but remains under significant pressure with a bearish technical outlook. The company faces declining same-store sales, a major franchisee bankruptcy, and net income margin compression from 7.58% in 2025 to 5.72% projected for 2026. Despite beating earnings expectations in recent quarters, valuation metrics appear attractive with P/E of 9.45 and P/S of 0.54, though high debt levels and competitive pressures persist.
The investment case hinges on new CEO Bob Wright's turnaround execution against substantial headwinds. While the stock trades at a discount to analyst consensus target of $7.58, near-term risks from franchisee instability and market share losses to burger chain competitors outweigh valuation appeal. Recovery depends on reversing sales trends and managing $2.66 billion in long-term debt effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
